Clinical TrialApr 21, 2026, 10:28 AM
Immatics to Present 4 Oral Presentations on PRAME Programs at ASCO 2026
AI Summary
Immatics N.V. announced that all four of its submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will cover updated clinical data for its PRAME cell therapies, including anzu-cel and IMA203CD8, across various cancers like melanoma, gynecologic cancers, and synovial sarcoma. Additionally, first-in-human results for the MAGEA4/8 bispecific, IMA401, will be presented, underscoring the continued advancement of Immatics' PRAME franchise in developing novel immunotherapies for solid tumors.
Key Highlights
- Immatics to deliver 4 oral presentations at the 2026 ASCO Annual Meeting.
- Presentations include Phase 1b clinical data on anzu-cel in advanced melanoma.
- Updated Phase 1a/1b data for IMA203CD8 in gynecologic cancers will be shared.
- Phase 1 results for PRAME cell therapies in synovial sarcoma to be presented.
- First-in-human results for MAGEA4/8 bispecific IMA401 across multiple cancers.
Price Impact
More from IMTX